Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $79.08 | 4 | 80.1% |
| Education | $19.69 | 1 | 19.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $20.87 | 1 | $0 (2021) |
| Horizon Therapeutics plc | $20.31 | 1 | $0 (2021) |
| PFIZER INC. | $19.92 | 1 | $0 (2023) |
| Aurinia Pharma U.S., Inc. | $19.69 | 1 | $0 (2021) |
| Amgen Inc. | $17.98 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17.98 | 1 | Amgen Inc. ($17.98) |
| 2023 | $19.92 | 1 | PFIZER INC. ($19.92) |
| 2021 | $60.87 | 3 | Teva Pharmaceuticals USA, Inc. ($20.87) |
All Payment Transactions
5 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/18/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $17.98 | General |
| Category: Inflammation/Rare Disease | ||||||
| 05/16/2023 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $19.92 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 08/24/2021 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Education | In-kind items and services | $19.69 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 06/02/2021 | Teva Pharmaceuticals USA, Inc. | — | Food and Beverage | In-kind items and services | $20.87 | General |
| 05/04/2021 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $20.31 | General |
| Category: KRYSTEXXA | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 261 | 479 | $62,387 | $31,191 |
| 2022 | 4 | 240 | 470 | $68,952 | $30,871 |
| 2021 | 4 | 258 | 508 | $91,185 | $35,221 |
| 2020 | 6 | 297 | 537 | $63,822 | $26,881 |
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 155 | 339 | $43,053 | $21,658 | 50.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 47 | 62 | $11,036 | $6,586 | 59.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 40 | 47 | $4,230 | $1,879 | 44.4% |
| 20610 | Aspiration and/or injection of fluid from large joint | Facility | 2023 | 19 | 31 | $4,068 | $1,069 | 26.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 153 | 351 | $51,246 | $23,135 | 45.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 40 | 50 | $10,200 | $5,121 | 50.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 34 | 45 | $4,635 | $1,680 | 36.2% |
| 20610 | Aspiration and/or injection of fluid from large joint | Facility | 2022 | 13 | 24 | $2,871 | $934.87 | 32.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 161 | 360 | $64,070 | $24,267 | 37.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 52 | 79 | $19,380 | $8,014 | 41.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 31 | 44 | $5,576 | $1,916 | 34.4% |
| 20610 | Aspiration and/or injection of large joint or joint capsule | Facility | 2021 | 14 | 25 | $2,159 | $1,025 | 47.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 155 | 343 | $43,752 | $17,991 | 41.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 61 | 91 | $8,139 | $3,090 | 38.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 25 | 34 | $5,814 | $2,793 | 48.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 20 | 23 | $2,737 | $1,386 | 50.6% |
| 20610 | Aspiration and/or injection of large joint or joint capsule | Facility | 2020 | 20 | 28 | $1,922 | $941.38 | 49.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 16 | 18 | $1,458 | $679.17 | 46.6% |
About Dr. Michelle Ryan, MD
Dr. Michelle Ryan, MD is a Rheumatology healthcare provider based in Corvallis, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1912019217.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michelle Ryan, MD has received a total of $98.77 in payments from pharmaceutical and medical device companies, with $17.98 received in 2024. These payments were reported across 5 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($79.08).
As a Medicare-enrolled provider, Ryan has provided services to 1,056 Medicare beneficiaries, totaling 1,994 services with total Medicare billing of $124,164. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Practice Information
- Specialty Rheumatology
- Other Specialties Rheumatology
- Location Corvallis, OR
- Active Since 08/31/2006
- Last Updated 11/06/2020
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1912019217
Products in Payments
- KRYSTEXXA (Biological) $38.29
- XELJANZ (Drug) $19.92
- LUPKYNIS (Drug) $19.69
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.